BIIB
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FBIIB.O%2Fkey-developments%2Farticle%2F2726877&ei=oIaaUqDjE4qw0AGZAw&usg=AFQjCNHqx2crW611F3wUKI7MLbCsjd6Q7A
Biogen Idec Inc Completes Purchase Of Full Rights And Control Of TYSABRI
Tuesday, 2 Apr 2013 04:30pm EDT
Biogen Idec Inc announced that it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI. The transaction was originally announced on February 6, 2013.Â 
